Selenium levels in human breast carcinoma tissue are associated with a common polymorphism in the gene for SELENOP (Selenoprotein P)  by Ekoue, Dede N. et al.
CS
a
D
K
a
b
c
d
a
A
R
R
A
K
S
B
P
S
S
G
G
M
M
1
f
a
f
s
i
s
e
c
H
a
c
d
(
C
(
h
0
4Journal of Trace Elements in Medicine and Biology 39 (2017) 227–233
Contents lists available at ScienceDirect
Journal  of  Trace  Elements  in  Medicine  and  Biology
jo ur nal ho me page: www.elsev ier .com/ locate / j temb
linical  studies
elenium  levels  in  human  breast  carcinoma  tissue  are  associated  with
 common  polymorphism  in  the  gene  for  SELENOP  (Selenoprotein  P)
ede  N.  Ekouea,  Soﬁa  Zaichicka, Klara  Valyi-Nagya, Matthew  Picklob, Craig  Lacherb,
ent Hoskinsc,  Michael  A.  Warsod,  Marcelo  G.  Boninia,c, Alan  M.  Diamonda,∗
Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
USDA-ARS, Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA
Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 26 August 2016
eceived in revised form 3 November 2016
ccepted 4 November 2016
eywords:
elenium
reast cancer
olymorphisms
ELENOP
a  b  s  t  r  a  c  t
Selenium  supplementation  of the  diets  of rodents  has  consistently  been  shown  to suppress  mammary
carcinogenesis  and some,  albeit  not  all, human  epidemiological  studies  have  indicated  an  inverse  asso-
ciation  between  selenium  and breast  cancer  risk.  In  order  to better  understand  the  role  selenium  plays
in breast  cancer,  30 samples  of tumor  tissue  were  obtained  from  women  with  breast  cancer  and  ana-
lyzed  for  selenium  concentration,  the  levels  of several  selenium-containing  proteins  and  the levels  of  the
MnSOD  anti-oxidant  protein.  Polymorphisms  within  the  genes  for  these  same  proteins  were  determined
from  DNA  isolated  from  the  tissue  samples.  There  was  a wide  range  of  selenium  in  these  tissues,  ranging
from  24  to  854  ng/gm.  The  selenium  levels  in the  tissues  were  correlated  to  the  genotype  of  the SELENOP
selenium  carrier  protein,  but  not  to other  proteins  whose  levels  have  been  reported  to be  responsiveelenoprotein P
PX1
lutathione peroxidase-1
anganese superoxide dismutase
nSOD
to  selenium  availability,  including  GPX1,  SELENOF  and  SBP1.  There  was  an association  between  a  poly-
morphism  in  the gene  for  MnSOD  and the levels  of the  encoded  protein.  These  studies  were  the  ﬁrst to
examine  the relationship  between  selenium  levels,  genotypes  and  protein  levels  in human  tissues.  Fur-
thermore,  the  obtained  data  provide  evidence  for the  need  to  obtain  data  about  the  effects  of  selenium
in  breast  cancer  by  examining  samples  from  that particular  tissue  type.
thor©  2016  The  Au
. Introduction
Selenium is an essential micronutrient that has long been the
ocus of attention as a potential chemopreventive supplement and
s a possible modiﬁer of disease outcomes. This is particularly true
or the possible role of selenium in cancer etiology where several
tudies have indicated an inverse association between selenium
ntake and cancer risk [1]. A recent meta-analysis of observational
tudies indicated that the selenium status of women, measured
ither by serum or toenail measurements, was  inversely asso-
iated with breast cancer risk of 0.65 [95%, CI 0.16–0.03] [2].
owever, analyses conducted by others did not indicate an associ-
tion between selenium levels and breast cancer incidence [3,4]. In
ontrast, the use of model systems has revealed a consistent ability
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of low levels of selenium provided to the diet of rodents to reduce
the incidence of carcinogen induced mammary tumors [5,6] and
this result has been reproduced in a recent publication [7].
Conﬂicting results between animal and human studies, and even
between human observational studies can be due to a host of intrin-
sic and extrinsic factors. Selenium delivery to tissues, including the
breast, is largely controlled by SELENOP (Selenoprotein P, SEPP1),
the most abundant selenium containing protein in plasma that
delivers selenium from the liver to distal sites [8–11]. Consistent
with the reports of an inverse association between selenium levels
and increased cancer risk, low levels of SELENOP have also been
associated with increased risk of cancers of the lung, colon, esoph-
agus, prostate and kidney [12–15]. Polymorphisms in the SELENOP
gene have been investigated for their association with cancer risk.
These include rs3877899 which results in either a threonine or
alanine at amino acid position 234 and rs7579 located in the 3′-
untranslated region (3′-UTR) that include regulatory sequences
which impacts translational efﬁciency during protein synthesis
[16–18]. These polymorphisms are linked to an increased risk of
several cancers, including breast cancer [14,19]. In some cases, the
impact of these polymorphisms on cancer risk was  shown to be
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Demographic and tumor characteristics of subjects.
Characteristic n % Missing
Ethnicity
Black 20 67% 0
White 6 20%
Other 4 13%
Age
20–39 4 13% 0
40–49 5 17%
50–59 9 30%
60–69 9 30%
70–79 3 10%
Diagnosis
Ductal 8 27% 0
Ductal & DCIS 14 47%
Lobular 3 10%
Other 5 17%
Subtype
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GHormone + (ER or PR) 18 67% 3
HER2 + 11 41%
Triple Negative 3 11%
odiﬁed by selenium levels, gender, and the polymorphisms in
he genes for other selenoproteins [13,15,20,21].
An interaction between SELENOP and manganese superoxide
ismutase (MnSOD), a mitochondrial protein that detoxiﬁes super-
xide, and cancer risk has been revealed in human studies. A variant
nSOD allele encoding an alanine (Ala) rather a valine (Val) at
odon 16 has been described (rs4880), and in several reports, has
een associated with an elevated breast cancer risk [22–24]. As
 consequence of Ala being at this position in the mitochondrial
mport signal peptide, there is increased transport of MnSOD into
he mitochondria as well as increased MnSOD mRNA stability [25].
nSODAla has been shown to interact with either a low selenium
ntake or the SELENOP polymorphism at position 234 to increase
he risk of cancer, although these studies were limited to prostate
ancer [26,27].
In order to contribute to the understanding of the role played by
elenium in breast cancer, 30 breast tumor samples were obtained
nd were analyzed for selenium content, genotyped for several
elenoproteins including SELENOP, as well as another antioxidant
rotein, MnSOD, and analyzed for the levels of MnSOD and other
elected proteins.
. Materials and methods
.1. Source of tissues
Thirty breast cancer tissue samples were obtained from the UIC
ancer Center Core (demographic information for the breast cancer
atients is found in Table 1). The tissue samples were archived, de-
dentiﬁed and obtained under an approved IRB. Genomic DNA from
hese breast tissues was isolated using the Complete DNA and RNA
uriﬁcation Kit (Epicentre, Madison, WI).
.2. Genotyping
Genotyping at the GPX1, MnSOD, SELENOF, and SELENOP1 loci
as accomplished by PCR ampliﬁcation of the desired region using
ene speciﬁc primers (Integrated DNA Technologies, Coralville, IA)
nd sequence analysis across the polymorphic region. PCR and
equencing primers used in the analysis as well as the size of the
mplicon are found in Appendix A. All sets of PCR reactions included
1 Nomenclature used for selenoproteins are consistent with that described by
ladyshev et al., J. Biol. Chem. PMID 27645994, 2016.edicine and Biology 39 (2017) 227–233
a control without template DNA. The sizes of the PCR products
were assessed by electrophoresis using a 1% agarose gel and bands
were visualized with ethidium bromide (Bio-Rad, Hercules, CA).
Sequencing was performed by the UIC DNA Core. Single-nucleotide
heterozygosity was apparent when 2 peaks are visualized at the
same location on the chromatogram that corresponded to the poly-
morphism of interest.
2.3. Selenium determination
Tissue selenium levels were determined at the USDA-ARS Grand
Forks Human Nutrition Research Center (Grand Forks, ND). For tis-
sue analysis, an aliquot of solid sample was  weighed and solubilized
by gentle reﬂuxing with nitric acid and hydrogen peroxide (H2O2).
After cooling, the samples were diluted to a 10 mL ﬁnal volume and
then analyzed on a Perkin Elmer ICP-MS Nexion 350D (Perkin Elmer
Corp., Wellsley, MA)  as previously described [28]. The maximum
limit of detection (MDL) was 0.18 ng/mL and the linear correla-
tion coefﬁcient of 0.999774. Samples were validated against three
digestion blanks and three National Institute of Standards and Tech-
nology (NIST) SRM 1577b Bovine Liver standards per set along with
a Continuing Calibration Veriﬁcation (CCV) and a Continuing Blank
Veriﬁcation (CCB) every 10 samples. The average recovery of the
Bovine Liver SRM 1577b NIST standard (Gaithersburg, MD  20899)
was 108.5%.
2.4. Protein quantiﬁcation
Protein concentration of cleared lysates was  determined using
the BCA assay (ThermoFisher Scientiﬁc, Waltham, MA). The pro-
tein was  prepared in RIPA buffer, sonicated and incubated on ice
for 2 h and analyzed by electrophoresis on NuPAGE 4–12% Bis-Tris
denaturing polyacrylamide gels (Invitrogen, Carlsbad, CA) followed
by transfer to a nitrocellulose membrane (Whatman Inc, Sanford,
ME). Membranes were blocked in 5% nonfat milk in tris-buffered
saline (TBS, Bio-Rad, Hercules, CA) for 1 h at room temperature, and
then incubated with primary antibody (mouse anti-GPX1 1:1000
(MBL International Corporation, Woburn, MA)), rabbit anti-MnSOD,
1:2000 (Millipore, Billerica, MA), anti-SBP1 1:1000 (MBL Inter-
national Corporation, Woburn, MA), rabbit anti-Actin, 1:15,000
(Abcam, Cambridge, MA), in TBS + Tween (TBS-T) overnight at 4 ◦C.
After 3 × 15 min washes, the membranes were incubated with
either the IRDye secondary antibody for rabbit/mouse, 1:15000
(LI-COR Biosciences, Lincoln, NE) for 2 h at room temperature or
anti- mouse IgG HRP-linked antibody, 1:10000 (Jackson Immuno
Research Labs, West Grove, PA) for 1hr at room temperature. Mem-
branes were washed 3 × 15 min  each, and analyzed by infrared
detection using the LI-COR Odyssey Imaging System or detected
by enhanced chemiluminescence with ECL plus (GE life Sciences,
Pittsburgh, PA). The signal was normalized to that obtained for actin
and protein levels were quantiﬁed by densitometry or ﬂuorescence
detection using the LI-COR system.
2.5. Statistics
Statistical analysis was performed with Graphpad Instat using
two-tailed paired t-test for Western blot analyses or the Mann-
Whitney test, two tailed and the ANOVA One-way analysis of
variance test with a post-hoc test for selenium analyses by geno-
types. A value of p < 0.05 was considered statistically signiﬁcant.
3. Results3.1. Selenium levels in human breast cancer samples
Breast tissue was obtained from 30 patients whose demograph-
ics are presented in Table 1. Selenium levels in those tissues was
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Fig. 1. Higher selenium levels in breast tissues are associated with SELENOP rs3877899 AA genotype. Tissue selenium levels were analyzed by graphite furnace spectroscopy and
DNAs  (n = 30) were genotyped for SELENOP rs3877899 and rs7579. There were statistically signiﬁcant differences between means of serum selenium for all patients grouped
b 057, Tukey’s Multiple Comparison Test * = p < 0.05). The error bars indicate the standard
e  of serum selenium for patients grouped by SELENOP rs7579 (Mann-Whitney, two-tailed
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Table 2
Frequency of the GPX-1, MnSOD and SELENOF polymorphisms in the studied
population.
PP PL LL
GPX1 Genotype Frequency% 60 36.7 3.3
n  18 11 1
VV VA AA
MnSOD Genotype Frequency% 20 53.3 26.7
n  6 16 8
CC CT TTy  SELENOP rs3877899 genotype (ANOVA One-way analysis of variance test p < 0.0
rror  of the mean. There were no statistically signiﬁcant differences between means
 > 0.05).
etermined by ICP-MS and the amount determined varied widely,
anging from 26 to 854 ng/gm (Appendix B). The selenium levels in
issues can be inﬂuenced by many factors, including dietary intake
nd the levels of speciﬁc selenium-containing proteins in the sam-
les. Selenium is delivered to tissues by the selenium carrier protein
ELENOP and polymorphisms within the gene encoding SELENOP
ave been associated with the levels of the encoded proteins. The
requency of these SELENOP polymorphisms in the tissues was
etermined by PCR ampliﬁcation and sequencing (Fig. 1). While
o association was found between the polymorphism residing in
he 3′-UTR of the SELENOP mRNA (rs7899) and selenium levels,
here was a signiﬁcant association between the coding variation
s3877899 and tissue selenium, with the homozygous A-expressing
llele being associated with higher selenium levels (Fig. 1). No
ssociations were found between selenium levels and commonly
tudied polymorphisms in either the GPX1 or SELENOF selenopro-
eins (Appendix C, see Table 2 for allele frequencies).
.2. Selenoprotein levels in human breast cancer samples
There are 25 selenium containing proteins in humans that con-
ain selenium in the form of selenocysteine with differences in
issue distribution, and several of these are tightly regulated by
elenium [29,30]. Among these are the anti-oxidant selenopro-
ein glutathione peroxidase-1 (GPX1) and SELENOF (Selenoprotein
5, Sep15) located in the endoplasmic reticulum and shown to be
nvolved in quality control of protein folding [30]. The levels of
PX1 and SELENOF were examined in the breast tissue samples by
estern blotting (Fig. 2). SELENOF was only detectable in 5 samples
not shown) and was not considered further. GPX1 levels varied sig-
iﬁcantly although there were no associations between GPX1 levels
nd the selenium status of the same tissue.
Polymorphisms in the genes for both GPX1 and SELENOF are
elieved to affect the levels of each protein as a function of selenium
vailability [31,32], and DNA from each sample was  genotypedSELENOF Genotype Frequency% 26.7 53.3 20
n  8 16 6
for these polymorphisms (Table 2). Western blot data presented
in Fig. 2 did not reveal any associations among GPX1 geno-
types, protein levels or selenium status, although the less frequent
leucine-encoding GPX1 allele was represented mainly among het-
erozygotes, with only one homozygote in the sample set. Selenium
Binding Protein 1 (SBP1) is a selenium-associated protein which
does not contain a selenocysteine. Its levels have been shown to
be lower in cancers and low levels are associated with poor out-
come of several cancers, including breast cancer [33]. In addition, an
inverse association between the levels of SBP1 and GPX1 have been
reported for several tissue types [33]. SBP1 levels were determined
by western blotting (Fig. 2) and no association was apparent with
either selenium levels or the amount of GPX1 (data not shown).
3.3. An association between MnSOD genotype and levels in breast
tissuesAs summarized in the Introduction, a polymorphism in the gene
for MnSOD interacts with selenium to impact cancer risk. In order to
determine whether the polymorphism was  associated with altered
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Fig. 2. Levels of SBP1, MnSOD and GPX1 in breast tissues. Cleared lysates from breast tissues were analyzed for SBP1, MnSOD, GPX1 and SELENOF (not shown) levels by western
blot  using anti-SBP1, MnSOD, GPX1 and SELENOF antibodies. -Actin was used as an endogenous protein loading control. Protein levels were quantiﬁed using ﬂuorescence
d ed to -Actin (Appendix D). Patient samples (5, 6, 8, 16–18, 23, 24, and 30) were excluded
f reast tissue samples and the analysis of this protein was therefore excluded from further
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Fig. 3. Breast tissues of individuals that are heterozygous for the MnSODVal polymor-
phism have lower MnSOD levels. Breast tissue samples were genotyped and assessed
by  western blotting with anti-MnSOD antibodies and -Actin as the endogenous
protein loading control. Protein levels were quantiﬁed by densitometry and normal-
ized to -Actin. Twenty-one samples were used, resulting in the following genotype
distribution: MnSODVal/Val (n = 5) MnSODVal/Ala (n = 10) MnSODAla/Ala (n = 6). There
were statistically signiﬁcant differences between MnSOD levels and genotypes. The
MnSOD heterozygous allele was associated with lower MnSOD levels in the studiedetection (SBP1 and MnSOD) or by densitometry (GPX1 and SELENOF) and normaliz
rom  ﬁnal western analysis due to poor quality. SELENOF was  detectable in only 5 b
nalyses.
evels of MnSOD, the sequence identity of the variation in codon 16
as determined for the DNAs obtained from the 30 samples and
ompared to the levels of MnSOD determined by western blotting.
ig. 3 represents the quantiﬁcation of the western data presented
n Fig. 2 stratiﬁed by genotype. These data indicate that the MnSOD
enotype is associated with differing levels of MnSOD in these tis-
ues, with the MnSOD allele containing an alanine at position 16
MnSODAla) being associated with higher levels of the MnSOD pro-
ein.
. Discussion and conclusion
Few studies have reported selenium levels in human breast
issues. For example, one study examining tissues obtained from
omen in Nigeria [34] and another from India [35] reported tissue
elenium levels to be somewhat higher than we report herein. This
ifference may  reﬂect the methods used to quantify selenium or
he study population’s geographical location. Regional difference
n selenium intake can vary widely although people in both Nigeria
nd India typically have lower plasma/serum levels of selenium as
ompared to those living in the United States [36]. Variations in
evels of selenium may  reﬂect the precise location from which the
reast tissue was  obtained, although the lack of differences in the
oncentration of selenium obtained from different regions of breast
umors has been reported [37]. It is also possible that the observed
ariation in selenium levels reﬂects the inclusion of fat tissue in
he samples analyzed, which is likely to have less selenium. This
xplanation is unlikely as the tissue used for selenium determina-
ion and protein extraction, while different, were adjacent from the
ame sample. Examination of the -Actin bands in western data in
ig. 2 indicate that the protein extracts were of similar quality while
hose tissue samples that yielded poor protein quality (excluded in
ig. 2 and marked with an asterisk in Appendix D) did not have
elenium levels that could account for the overall variability.
Genetic differences among populations may  also account for dif-
erences in selenium levels. Polymorphisms in the SELENOP gene
re associated with the levels of selenium in plasma or toenails
18,38,39], but no studies to our knowledge have addressed the
elevance of SELENOP polymorphisms to selenium levels in human
issues. Two polymorphisms in the SELENOP gene were investi-
ated; one, rs3877899 resulting in either an alanine or threonine at
osition 234 of the coding sequence and the other, rs7579, resulting
n a G or A in the 3′ UTR of the gene. Only rs3877899 was asso-
iated with tissue selenium levels with those tissues expressing
he Thr/Thr homozygote being associated with signiﬁcantly more
elenium than either the Ala/Ala homozygote or heterozygotes.
he alanine-expressing allele has been associated with a reduced
isk of breast cancer [40] and elevated expression of anti-oxidant
elenoproteins [18,40], although there was no apparent associa-
ion between either selenium levels or SELENOP genotype and thepopulation (ANOVA One-way analysis of variance test p = 0.0132, Tukey’s Multiple
Comparison Test * = p< 0.05). The error bars represent the standard error of the mean.
levels of any of the selenium-containing proteins examined. The
reason for this is uncertain, but may  pertain to the form of sele-
nium present in the tissue which could not be determined by the
techniques employed in this study.
Allelic differences in MnSOD have been linked to increase risk
and worse outcome of several cancers [16,41]. An MnSOD allele that
results in an alanine at position 16 of the mitochondrial transloca-
tion sequence (MnSODAla) instead of a valine (MnSODVal) results in
more efﬁcient transport of the protein into the mitochondria, more
MnSOD protein and elevated activity [25]. The MnSODAla allele has
been associated with an increased risk of breast cancer in some,
but not all studies [41] and has been shown to interact with sele-
nium levels in determining prostate cancer risk [27]. In a large
cohort from the Women’s Health Study, MnSODAla was shown to
be associated with breast cancer risk only when present with the
codon 198 GPX1 leucine polymorphism, GPX1Leu [42]. The GPX1Leu
allele encodes a protein that is less responsive to selenium sup-
plementation when compared to the protein encoded by GPX1Pro
[32]. GPX1 allelic identity is therefore likely to impact the levels of
H2O2, the dismutase product of MnSOD and an important signaling
molecule, thus altering H2O2 responsive pathways implicated in
carcinogenesis. Little has been done to evaluate the consequences
of the amino acid at codon 16 directly in breast tissue, although one
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rimers Size (bp) Sequencing Primers
gccaccgcgcttatg 3’ 256 5’ gaccccaagctcatcacctg 3’
aaaacccccccgagac 3’
tagcaccagcactagcagcat 3’ 500 5’ cgcggcgctgactga 3’
27  239.5
28  143.9
29  579.5
30  391.9D.N. Ekoue et al. / Journal of Trace Elemen
tudy reported higher MnSOD enzyme activity in tissues derived
rom Jordanian women who were heterozygous at that location
s compared to MnSODVal homozygotes; however no MnSODAla
omozygotes were included in that study [43]. Here, higher MnSOD
rotein levels were detected in tissues derived from women who
ere homozygous for MnSODAla as compared to either MnSODVal
omozygotes or heterozygotes.
Human epidemiological studies have identiﬁed many poten-
ial etiological factors that can impact the risk of breast cancer.
hese include selenium status and genetic variations in the genes
or selenoproteins and anti-oxidant proteins, such as MnSOD. To
nderstand the role such variables play in breast cancer and other
athologies, it is necessary to assess mechanisms in the speciﬁc
issue of interest. This is perhaps highlighted by the previously
ublished meta-analysis which concluded that the inverse asso-
iation between the levels of selenium and breast cancer reached
tatistical signiﬁcance when serum but not toenail selenium levels
ere determined [2]. Towards the goal of investigating the relation-
hip between selenium levels and breast cancer, clinical samples
btained from tumors of the breast were used to determine sele-
ium levels, genotype and levels of several proteins. Associations
etween selenium status and SELENOP levels, as well as the asso-
iation between MnSOD genotype and the levels of the encoded
rotein were obtained in the breast tissue samples, as have been
een in other tissues. The lack of anticipated associations between
elenium and the levels of GPX1, SELENOF and SBP1 may  be due
o the sample size and further analysis of human tissues will be
equired for clariﬁcation of the relationships involved.
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ppendix A. PCR and primer sequences used for
enotyping analyses.
CR and primer sequences used for genotyping analyses.
Prim
Gene rs# Nucleotide Identity/Location Amino Acid PCR P
GPX1 rs1050450 C/T, codon 198 Pro/Leu F: 5’c
R: 5’g
MnSOD rs4880 T/C, codon 16 Val/Ala F: 5’g
R:  5’gcgttga
SELENOF rs5859 G/A, 3’UTR F: 5’cagactt
position 1125 R: 5’gccaag
SELENOP rs3877899 G/A, codon 234 Ala/Thr F: 5’ cacgca
rs7579  A/G, 3’UTR R: 5’ggaaatedicine and Biology 39 (2017) 227–233 231
Appendix B. Selenium levels in breast tissues.
Selenium levels in breast tissues.
Patient Se ng/g
1 626.3
2  252.9
3  315.4
4  308.9
5  230
6  852.7
7  295.1
8  116.8
9  258.8
10  287.4
11  158.4
12  260.8
13  218
14  26.3
15  211.3
16  474.8
17  389.3
18  427.8
19  334
20  222.6
21  152.3
22  143.4
23  580.1
24  88.9
25  392.9
26  267.4tgtgaggttccag 3’
gcggttaattatg 3’ 413 5’cagacttgcggttaattatg 3’
tatgtatctgatcc 3’
ttattcctatctctataagcttg 3’ 722 5’cacgcattattcctatctctataagcttg 3’
gaaattgtgtctagactaaattgg 3’
2A
s
e
y
A
s
M
e
w
(
p
R
a
a
(
n
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ppendix C.
Selenium levels are not associated with GPX1 or SELENOF genotypes. Breast tissue samples (n = 30) were genotyped and selenium level
in these tissues were analyzed by ICP-MS Spectrometry. There were no statistically signiﬁcant differences between means of tissu
selenium for all patients grouped by GPX1 genotype (Mann-Whitney, two-tailed p > 0.05) and SELENOF genotypes (ANOVA One-wa
analysis of variance test p > 0.05, Tukey’s Multiple Comparison Test p > 0.05).
ppendix D. Relative protein levels in breast tissues. Tissue
amples were assessed by western blotting with anti-SBP1,
nSOD and GPX1 antibodies and -Actin as the
ndogenous protein loading control (Fig. 2). Protein levels
ere quantiﬁed by densitometry and normalized to -Actin
* = excluded from the ﬁnal western analysis due to poor
rotein quality.)
elative protein levels in breast tissues. Tissue samples were
ssessed by western blotting with anti-SBP1, MnSOD and GPX1
ntibodies and ˇ-Actin as the endogenous protein loading control
Fig. 2). Protein levels were quantiﬁed by densitometry and
ormalized to ˇ-Actin (* = excluded from the ﬁnal western
nalysis due to poor protein quality.)
Protein Levels Normalized to Actin
Patient SBP1 MnSOD GPX1
1 1.74 0.45 0.45
2  0.37 2.17 0.87
3  46.68 0.22 1.88
4  4.69 0.53 0.80
*5  0.01 0.01 0.00
*6  250.51 3.59 6.56
7  2.17 0.49 0.86
*8  73.19 0.24 0.10
9  6.88 1.08 1.09
10  27.32 0.69 1.08
11  4.19 1.19 1.28
12  62.35 0.34 1.42
13  41.30 0.43 1.30
14  2.20 0.82 1.06
15  145.82 0.39 3.61
*16  40.87 0.74 0.00
*17  10.14 0.23 0.35
*18  0.36 0.01 0.00
19  6.63 0.70 1.12
20  57.29 0.32 1.62
21  36.15 1.35 1.11
22  38.65 0.33 0.67
*23  2.12 0.13 0.00
*24  179.67 0.78 0.00
25  8.54 1.09 1.40
26  23.06 0.40 2.77
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